Prostate-specific antigen velocity and repeated measures of prostate-specific antigen

被引：42

作者：

Carter, HB

Pearson, JD

机构：

[1] JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205

[2] JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205

[3] MERCK & CO INC,DIV RES,W POINT,PA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 1997年 / 24卷 / 02期

关键词：

D O I：

10.1016/S0094-0143(05)70380-3

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate-specific antigen velocity (PSAV), or rate of change in PSA, is a concept that considers the changes in PSA between measurements adjusted for the elapsed time between the measurements. Because there is substantial individual variability between PSA measurements, a simple change in PSA is not useful as a marker for prostate cancer; however, studies suggest that if PSAV is evaluated during at least 1.5 to 2 years, (1) less than 5% of men without prostate cancer have a PSAV of 0.75 ng/mL per year or more and (2) more than 70% of men with prostate cancer have a PSAV of 0.75 ng/mL, per year or more. These data suggest that PSAV is a specific marker for prostate cancer that can be used as one method for assessing the risk that prostate cancer is present.

引用

收藏

页码：333 / &

页数：7

相关论文

共 15 条

[1]

Carter H. Ballentine, 1995, Journal of Urology, V153, p419A

[2] PROSTATE-SPECIFIC ANTIGEN VARIABILITY IN MEN WITHOUT PROSTATE-CANCER - EFFECT OF SAMPLING INTERVAL ON PROSTATE-SPECIFIC ANTIGEN VELOCITY [J].

CARTER, HB ;

PEARSON, JD ;

WACLAWIW, Z ;

METTER, EJ ;

CHAN, DW ;

GUESS, HA ;

WALSH, PC .

UROLOGY, 1995, 45 (04) :591-596

[3] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].

CARTER, HB ;

PEARSON, JD ;

METTER, J ;

BRANT, LJ ;

CHAN, DW ;

ANDRES, R ;

FOZARD, JL ;

WALSH, PC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220

[4] COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].

CATALONA, WJ ;

RICHIE, JP ;

AHMANN, FR ;

HUDSON, MA ;

SCARDINO, PT ;

FLANIGAN, RC ;

DEKERNION, JB ;

RATLIFF, TL ;

KAVOUSSI, LR ;

DALKIN, BL ;

WATERS, WB ;

MACFARLANE, MT ;

SOUTHWICK, PC .

JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290

[5] PROSTATE-CANCER DETECTION IN A CLINICAL UROLOGICAL PRACTICE BY ULTRASONOGRAPHY, DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN [J].

COONER, WH ;

MOSLEY, BR ;

RUTHERFORD, CL ;

BEARD, JH ;

POND, HS ;

TERRY, WJ ;

IGEL, TC ;

KIDD, DD .

JOURNAL OF UROLOGY, 1990, 143 (06) :1146-1154

[6] A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER [J].

GANN, PH ;

HENNEKENS, CH ;

STAMPFER, MJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04) :289-294

[7] THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].

GORMLEY, GJ ;

STONER, E ;

BRUSKEWITZ, RC ;

IMPERATOMCGINLEY, J ;

WALSH, PC ;

MCCONNELL, JD ;

ANDRIOLE, GL ;

GELLER, J ;

BRACKEN, BR ;

TENOVER, JS ;

VAUGHAN, ED ;

PAPPAS, F ;

TAYLOR, A ;

BINKOWITZ, B ;

NG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1185-1191

[8] Pitfalls in interpreting prostate specific antigen velocity [J].

Kadmon, D ;

Weinberg, AD ;

Williams, RH ;

Pavlik, VN ;

Cooper, P ;

Migliore, PJ .

JOURNAL OF UROLOGY, 1996, 155 (05) :1655-1657

[9] Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population [J].

Komatsu, K ;

Wehner, N ;

Prestigiacomo, AF ;

Chen, ZX ;

Stamey, TA .

UROLOGY, 1996, 47 (03) :343-346

[10]

METTLIN C, 1994, CANCER, V74, P1615, DOI 10.1002/1097-0142(19940901)74:5<1615::AID-CNCR2820740520>3.0.CO